![Øystein Rekdal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 201 262 $ al 31/05/2026
Øystein Rekdal is the founder of Lytix Biopharma AS, serving as Chief Executive Officer & Media Relations Contact since 2019, founded in 2003.
Dr. Rekdal is a Professor at the University of Tromso.
Formerly, Dr. Rekdal worked as Director at Prophylix AS.
Education includes a doctorate from the University of Tromso.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LYTIX BIOPHARMA ASA 0,23 % | 11/12/2025 | 176.179 ( 0,23 % ) | 201 262 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LYTIX BIOPHARMA ASA | Director Ejecutivo | 11/09/2019 |
University of Tromso
 University of Tromso Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Empresas | Cargo | Fin |
|---|---|---|
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
University of Tromso
University of Tromso Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lytix Biopharma AS
 Lytix Biopharma AS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops novel cancer immunotherapies | Health Technology |
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
